IMMX · Immix Biopharma Inc
United States · RS rating 41 · As of 2026-11-03
| Price | 7.71 USD |
|---|---|
| 1-day change | +6.2% |
| RS rating (overall / 1M / 3M / 12M) | 41 / 17 / 32 / 94 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 33 / 36 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +46.7% |
| Market cap (USD) | $539.1M |